Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226219435> ?p ?o ?g. }
- W4226219435 endingPage "735" @default.
- W4226219435 startingPage "727" @default.
- W4226219435 abstract "More than two-thirds of patients with breast cancer present with hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative disease at their initial diagnosis. HR-positive breast cancer's growth depends on Cyclin D1, a direct transcriptional target of estrogen receptors (ER). The recent introduction of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors (palbociclib, ribociclib, and abemaciclib) has revolutionized the treatment of metastatic HR-positive, HER2-negative breast cancer in both endocrine-sensitive and endocrine-resistant settings and in both pre-and post-menopausal women. Multiple large randomized clinical trials had demonstrated improvement in progression-free survival (PFS) and, more recently, in overall survival (OS). Adjuvant endocrine therapy (ET) significantly reduces the risk of recurrence and death among patients with HR-positive early-stage breast cancer (EBC). However, up to 20% of these patients will experience local, regional or distal recurrences in the first ten years. Such resistance to ET motivated researchers to try CDK4/6 inhibitors in EBC, both in adjuvant and neoadjuvant settings. While many clinical trials are still ongoing, at least one study and two meta-analyses had shown beneficial results, based on which the US Food and Drug Administration had recently approved the use of one of these agents, abemaciclib, in combination with ET for the adjuvant therapy of patients with high-risk EBC. In this paper, we review the recently published and ongoing landmark clinical trials attempting to expand the use of CDK4/6 inhibitors, in combination with ET, in the adjuvant setting of EBC." @default.
- W4226219435 created "2022-05-05" @default.
- W4226219435 creator A5032290025 @default.
- W4226219435 creator A5062675922 @default.
- W4226219435 date "2022-03-01" @default.
- W4226219435 modified "2023-09-26" @default.
- W4226219435 title "Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting" @default.
- W4226219435 cites W11697548 @default.
- W4226219435 cites W1988050012 @default.
- W4226219435 cites W2091015937 @default.
- W4226219435 cites W2127457632 @default.
- W4226219435 cites W2144790402 @default.
- W4226219435 cites W2152793272 @default.
- W4226219435 cites W2159427817 @default.
- W4226219435 cites W2188229458 @default.
- W4226219435 cites W2214665719 @default.
- W4226219435 cites W2279220517 @default.
- W4226219435 cites W2285220377 @default.
- W4226219435 cites W2290950904 @default.
- W4226219435 cites W2552099557 @default.
- W4226219435 cites W2587766207 @default.
- W4226219435 cites W2601260249 @default.
- W4226219435 cites W2617437931 @default.
- W4226219435 cites W2620993107 @default.
- W4226219435 cites W2745775556 @default.
- W4226219435 cites W2760817089 @default.
- W4226219435 cites W2761190519 @default.
- W4226219435 cites W2763875663 @default.
- W4226219435 cites W2772666421 @default.
- W4226219435 cites W2799839262 @default.
- W4226219435 cites W2804105316 @default.
- W4226219435 cites W2804365213 @default.
- W4226219435 cites W2805575723 @default.
- W4226219435 cites W2884327845 @default.
- W4226219435 cites W2896846857 @default.
- W4226219435 cites W2908699784 @default.
- W4226219435 cites W2931385471 @default.
- W4226219435 cites W2945156880 @default.
- W4226219435 cites W2946615942 @default.
- W4226219435 cites W2947828688 @default.
- W4226219435 cites W2948069739 @default.
- W4226219435 cites W2976415870 @default.
- W4226219435 cites W2980534320 @default.
- W4226219435 cites W2990894089 @default.
- W4226219435 cites W2995593755 @default.
- W4226219435 cites W3020482066 @default.
- W4226219435 cites W3031130887 @default.
- W4226219435 cites W3116228263 @default.
- W4226219435 cites W3128646645 @default.
- W4226219435 cites W3133509869 @default.
- W4226219435 cites W3136354293 @default.
- W4226219435 cites W3147142721 @default.
- W4226219435 cites W3148345241 @default.
- W4226219435 cites W3166207926 @default.
- W4226219435 cites W3167364940 @default.
- W4226219435 cites W3177242453 @default.
- W4226219435 cites W3181616727 @default.
- W4226219435 cites W3195237310 @default.
- W4226219435 cites W3202446623 @default.
- W4226219435 cites W3206169364 @default.
- W4226219435 cites W4200066800 @default.
- W4226219435 cites W4206349107 @default.
- W4226219435 doi "https://doi.org/10.2147/dddt.s356757" @default.
- W4226219435 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35321498" @default.
- W4226219435 hasPublicationYear "2022" @default.
- W4226219435 type Work @default.
- W4226219435 citedByCount "0" @default.
- W4226219435 crossrefType "journal-article" @default.
- W4226219435 hasAuthorship W4226219435A5032290025 @default.
- W4226219435 hasAuthorship W4226219435A5062675922 @default.
- W4226219435 hasBestOaLocation W42262194351 @default.
- W4226219435 hasConcept C121608353 @default.
- W4226219435 hasConcept C126322002 @default.
- W4226219435 hasConcept C143998085 @default.
- W4226219435 hasConcept C23589133 @default.
- W4226219435 hasConcept C2775930923 @default.
- W4226219435 hasConcept C2777176818 @default.
- W4226219435 hasConcept C2777863537 @default.
- W4226219435 hasConcept C2777982462 @default.
- W4226219435 hasConcept C2778812593 @default.
- W4226219435 hasConcept C2779744173 @default.
- W4226219435 hasConcept C2779786085 @default.
- W4226219435 hasConcept C530470458 @default.
- W4226219435 hasConcept C535046627 @default.
- W4226219435 hasConcept C71924100 @default.
- W4226219435 hasConcept C84606932 @default.
- W4226219435 hasConceptScore W4226219435C121608353 @default.
- W4226219435 hasConceptScore W4226219435C126322002 @default.
- W4226219435 hasConceptScore W4226219435C143998085 @default.
- W4226219435 hasConceptScore W4226219435C23589133 @default.
- W4226219435 hasConceptScore W4226219435C2775930923 @default.
- W4226219435 hasConceptScore W4226219435C2777176818 @default.
- W4226219435 hasConceptScore W4226219435C2777863537 @default.
- W4226219435 hasConceptScore W4226219435C2777982462 @default.
- W4226219435 hasConceptScore W4226219435C2778812593 @default.
- W4226219435 hasConceptScore W4226219435C2779744173 @default.
- W4226219435 hasConceptScore W4226219435C2779786085 @default.
- W4226219435 hasConceptScore W4226219435C530470458 @default.